FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Related Content

US FDA Should Offer Formal Declaration Of Orphan Drug Flexibility, Attorney Says

US FDA's Rare Diseases Program Not Expected To Change With Drug Office Reorg

Gottlieb Q&A: Confirmation Is Nearing, Will Complete Response Letters Finally Get Released?

BioMarin's Brineura Approval Shows FDA's Open Door For Orphan Drugs

Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

IRB Process Streamlining Expected In 21^st Century Cures Bill

PDUFA V: Accelerated Approval Expansion May Outshine Rare Disease Improvements

Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?

Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds